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Introduction
Colon cancer is a highly prevalent disease and the fourth 
most common cause of cancer death in western countries (1). 
The currently accepted standard of care in locally advanced 
colon cancer (LACC) is complete surgical excision followed 
by adjuvant chemotherapy. This approach achieves 5-year 
survival rates varying from 73% to 28%, depending on the 
stage III subgroup analyzed (2). 
Several recent trials have been developed in order to 
assess the role of neoadjuvant chemotherapy in LACC (3-5), 
resembling its use in other locally advanced tumors (6,7). 
Besides the risk of tumor progression during the induction 
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therapy, one of the most important challenges of this 
approach is the accuracy of baseline computed tomography 
(CT) scan to properly select patients who may benefit most 
from this strategy. The scarce available data in this setting 
is partly responsible for the lack of a more widespread use 
of neoadjuvant chemotherapy, despite its several theoretical 
benefits. 
The aim of the present study is to assess the accuracy of 
CT scan in the staging of these patients and to correlate 
radiological, metabolic and pathological changes found 
after preoperative oxaliplatin and fluoropyrimidine-based 
chemotherapy. 
Material and methods
The study included patients with LACC who completed 
preoperative chemotherapy and surgery within a tertiary 
center. Eligibility and exclusion criteria have been reported 
elsewhere (5). Eligibility criteria included age >18 years, 
diagnosis of adenocarcinoma by biopsy, Karnofsky performance 
status >60% or ECOG <2, Haemoglobin >10 g/dL, 
white blood cell >3.0×109/L, Total Bilirubin <25 mcromol/L, 
glomerular filtration rate >50 mL/min, absence of important 
comorbidity, and able and willing to provide written informed 
consent for the study. Radiological signs of suspicious 
lymph nodes and/or transmural depth invasion by CT were 
mandatory. Rectal tumours, distant metastases, peritoneal 
carcinomatosis by CT or positron emission tomography 
(PET)/CT scan, and complete colonic obstruction were 
considered exclusion criteria.
All patients received induction chemotherapy with 
oxaliplatin and capecitabine on a biweekly basis. The study 
protocol was approved by the Institutional Review Board.
T h e  c l i n i c a l  s t a g i n g  w a s  b a s e d  o n  p h y s i c a l 
examination, colonoscopy with biopsy confirmation, and 
thoracoabdominopelvic CT scan. In fourteen patients, a 
whole-body 18Fluorodeoxyglucose (18FDG) PET-CT scan 
was also available.
CT scan protocol
The patients were examined using a multidetector CT 
(MDCT) Scanner Siemens 64 (Erlangen, Germany). 
CT scans were obtained with a tube current of 150 mA 
and 120 kV of voltage with a 480 mm field of view and a 
512×512 matrix. Oral contrast material [Diatrizoate sodium 
meglumine (Gastrografin; Bayer Hispania, SL, Saipan)] 
was administered before the study to achieve an adequate 
colonic opacification and distention. Intravenous non-ionic 
contrast  agent  (Omnipaque ® 300 mg iodine/mL; 
Nycomed, Hispania, SL, Saipan) was also administered. 
The standard CT acquisition protocol was performed in 
the venous phase—start delay of 70 seconds—to maximize 
the detection of eventual hepatic metastases. A section of 
5 mm width was performed. An intraluminal lesion with 
wall thickening but without surrounding tissue infiltration 
was defined as a T2 classification. Spiculated tissue 
extending from the colonic wall into the pericolic fat was 
characterized as a T3 classification. Colonic wall masses with 
infiltration of other surrounding organs were considered 
as T4 classification. Regional lymph node >0.8 cm 
in short axis diameter were considered pathologic. 
The tumor volume was measured using semiautomatic 
segmentation dedicated software (Volume Wizard®, 
Siemens Medical Solutions, Erlangen, Germany). In CT, 
absolute Hounsfield units (HU) correspond directly to 
the tissue property. Thus, a predefined soft tissue window 
display setting (300 to 45 HU) was applied to determine 
the tumor volume. The tumor was manually defined and 
segmentation of the entire scanning volume was performed 
automatically, with manual adjustments when necessary. 
The tumor was measured across the total imaging volume 
and calculated in cubic centimeters (cc). Figure 1 shows the 
tumor volume estimation. 
PET-CT scan protocol
Patients were required to fast for 6 h. A blood glucose analysis 
was performed to ensure that levels were under 120 mg/dL. All 
patients received an intravenous injection of 6.29 MBq/kg 
of (18F)-FDG. One hour after the injection, (18F)-FDG-
PET/CT studies were performed using a Biograph DUO 
scanner (Siemens, Knoxville, TN, USA). PET emission 
images were acquired with patients in a supine position 
using the 3-D mode (field of view 50 cm in the transaxial 
plane and 15.5 cm in the axial plane), at three min per bed 
position. CT data were used for attenuation correction and 
anatomical location of PET emission data. Quantitative 
measurement was normalized for the dose administered and 
the weight of the patients [standardized uptake value (SUV)]. 
Response evaluation
A CT (or PET-CT) scan was repeated 3-4 weeks after the 
end of neoadjuvant chemotherapy in order to assess tumour 
response and to confirm the resectability.
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Radiologic response
The percentual tumor volume differences were calculated 
by CT. Three response categories were established: minor 
(volume reduction <33%), medium (33-66%) and major 
(>66%). Changes in T and N classification were also 
recorded.
Metabolic response
The results were categorized according to the definitions 
provided by the European Organisation for Research and 
Treatment of Cancer (EORTC) (8). Progressive metabolic 
disease was considered as an increase in [18F]-FDG tumor 
SUV of greater than 25% within the tumor region; stable 
metabolic disease as an increase in tumor [18F]-FDG SUV 
of less than 25% or a decrease of less than 25%; partial 
metabolic response as a reduction greater than 25% in 
tumor [18F]-FDG SUV; and complete metabolic response 
as the complete resolution of [18F]-FDG uptake within 
the tumor volume. Due to the necessity of bypassing 
chemotherapeutic effect and to avoid the fluctuation in 
18F-FDG uptake that may occur early after treatment 
(stunning or flare of tumor uptake) a minimum of ten days 
after the end of chemotherapy was required before PET/
TC performance (9).
Pathologic response
Pathologic staging was performed according to the TNM 
classification (2). Lymphovascular and perineural invasion, 
distal and circumferential margins were also documented. 
Tumor regression grade (TRG) was reported according to 
the scale proposed by Ruo et al. for rectal cancer (10). This 
classification considers 6 grades of response: grade 0 (no 
response to treatment), grade 1 (response <33%), grade 
2 (response between 33% and 66%), grade 3 (response 
between 66% and 94%), grade 3+ (95-99% response, focus 
or microscopic residual), and grade 4 [no viable tumor 
identified, pathological complete response (PCR)]. 
Relationship between radiologic, metabolic and pathologic 
findings
Correlation between radiological and pathological findings 
was assessed in order to determine the predictive value 
of the CT scan after neoadjuvant treatment. Accuracy, 
sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) were calculated for T stage, 
N stage and for TN stage. Relationship between tumor 
volume changes by CT scan, SUV-FDG uptake by PET, 
and pathologic response were also analysed.
Figure 1 Tumor volume estimation by CT scan. CT, computed tomography.
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Statistical analysis
All the statistical analyses were done using the SPSS/PC 
v.15 for Windows statistical package (SPSS, Chicago, IL, 
USA). Results were expressed as mean (standard deviation) 
or median (P25-P75) for continuous variables depending on 
whether normal distribution was followed or not. Proportion 
was used for qualitative variables. Relationship between 
variables were studied by Student-t (or Mann-Whitney U, 
Table 1 Radiologic response grade
Radiologic response grade N (%)
Low: <33% 5 (11.4)
Medium: 33-66% 18 (43.1)
High: >66% 19 (45.5)
Table 2 Metabolic response grade
Metabolic response grade N (%)
Progressive metabolic disease 0 (0)
Stable metabolic disease 4 (28.6)
Partial metabolic response 9 (63.9)
Complete metabolic response 1 (7.1)
Table 3 Pathologic characteristics of the surgical specimens
N [%]
Differentation grade
High 6 [13.6]
Moderate 37 [84.1]
Low 1 [2]
ypTNM
 ypT1-2N0 10 [22.3]
 ypT3-4 N0 19 [43.2]
 ypT1-2N+ 4 [9.1]
 ypT3-4N+ 11 [25.0]
TRG (MSKCC)
 0, 1, 2 27 [61.4]
 3 12 [27.3]
 3+, 4 5 [11.4]
Limphovascular invasion 10 [22.7]
Perineural invasion 8 [18.2]
Resected nodes* 22.3 [9.5]
*, Expressed as mean (standard deviation); TRG, tumor 
regression grade; MSKCC, Memorial Sloan-Kettering Cancer 
Center.
depending if data followed a normal distribution or did not) 
and χ2 tests. Student’s t or Wilcoxon test was also employed 
for paired samples. Association was measured by ANOVA 
and Spearman correlation. A P value <0.05 was considered 
significant.
Results
From July 2009 to June 2012, forty-four consecutive 
patients completed neoadjuvant treatment and underwent 
surgery. Median age was 66.8 years, 65.9% (29/44) of them 
were males and the mean BMI was 26.7 kg/m2 The most 
frequent tumor location was sigmoid colon (47.7%, 21/44) 
followed by ascending colon (34.1%, 15/44). 
Radiologic response
Radiologic response was reported in the 42 patients 
(95.5%) in which pre- and post-treatment CT scan data 
was available. All patients achieved a tumor reduction, with 
no patient presenting metastatic progressive disease during 
the neoadjuvant chemotherapy. Median baseline tumor 
volume was 51.0 cc (range, 28.9-75.5 cc) compared to 18.4 cc 
(range, 8.7-30.3 cc) after chemotherapy. This translates 
into a statistically significant reduction of 62.5% (range, 
38.3-81.8%) (P<0.001; Wilcoxon test). Table 1 shows the 
percentual tumor volume differences. The 61.9% (26/42) of the 
patients achieved a tumor volume reduction greater than 50%. 
Metabolic response
Pre and post chemotherapy PET-CT scan was available 
in fourteen patients. Median baseline SUV value was 
18.9 (range, 13.1-24) compared to 10.7 (range, 5.3-15.6) 
after treatment, for a median reduction of 38.9% (range, 
9.6-63.7%) (P=0.004; Wilcoxon test). The median interval 
between the end of chemotherapy and the pre-surgery 
PET/CT was 21.5 days (range, 16.8-22 days). As shown in 
Table 2, >70% (10/14) of the patients achieved a metabolic 
response.
Pathologic response
Table 3 summarizes the pathological findings of our study. 
Stage II and III disease was observed in 29/44 (65.9%) 
and 15/44 (34.1%) of the patients, respectively. Pathologic 
complete response was achieved in three patients. 38.7% 
(17/44) of the patients achieved a grade 3 or greater TRG. 
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Mean number of harvested nodes was 22.3 (9.5). Disease 
free resection margins were obtained in all cases. 
Radiologic and pathologic relation
T classification relation
We first aimed to find the relation between the T 
classification, classified by CT scan after chemotherapy, and 
the T classification depicted in the final pathogic report. 
As seen in Table 4, accuracy was 62% (27/44), with an 
understaging rate of 18% (8/44) and an overstaging rate of 
20.4 % (9/44). 
T0-2, were considered as Low T and T3-4, as High T. 
CT scan sensitivity, specificity, PPV and NPV for T 
classification were 87.1% (27/31), 61.6% (8/13), 84.4% 
(27/32) and 66.7% (8/12), respectively. 
N stage correlation
Secondly, a correlation between CT scan and pathologic 
report was assayed. As shown in Table 5, accuracy for N 
classification was 87% (38/44), with a 5% (2/44) rate of 
understaging and a 9.1% (4/44) rate of overstaging. 
CT scan sensitivity, specificity, PPV and NPV for N 
classification were 75.0% (12/16), 92.9% (26/28), 85.7% 
(12/14) and 86.7% (26/30), respectively, with a likelihood 
ratio of 10.6.
TN classification correlation
As shown in Table 6, accuracy for TN classification was 
77.3% (34/44), with an under- and overstaging rate of 
Table 4 Relationship between radiologic and pathologic T stage
CT scan 
Pathology
Understaging n [%] Overstaging n [%] Accuracy [%]
T0 T1 T2 T3 T4 Total
T0 2 0 1 0 0 3 1 [33] 0 [0] 67
T1 0 0 0 0 0 0 0 [0] 0 [0] –
T2 1 1 3 4 0 9 4 [44] 2 [22] 33
T3 0 0 3 22 3 28 3 [11] 3 [11] 79
T4 0 0 2 2 0 4 0 [0] 4 [100] 0
Total 3 1 9 28 3 44 8 [18] 9 [20] 62
Table 5 Relationship between radiologic and pathologic N stage
Pathology
Understaging n [%] Overstaging n [%] Accuracy [%]
N– N+ Total
N– 26 4 30 4 [13] 0 [0] 26 [87]
N+ 2 12 14 0 [0] 2 [14] 12 [87]
Total 28 16 44 4 [9] 2 [5] 38 [87]
Table 6 Relationship between radiologic and pathologic TN stage
CT Scan
Pathology
Understaging n [%] Overstaging n [%] Accuracy [%]
0 I II III Total
0 2 1 0 0 3 1 [33] 0 [0] 67
I 1 2 2 1 6 3 [50] 1 [17] 33
II 0 1 18 2 21 2 [10] 1 [0.5] 86
III 0 0 2 12 14 0 [0] 2 [14] 86
Total 3 4 22 15 44 6 [13,6] 4 [9.1] 77
CT, computed tomography.
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13.6% (6/44) and 9.1% (4/44), respectively. 
Relation between clinical and pathologic TRG
Correlation between the continuous percentual volume 
changes by CT scan before and after chemotherapy and 
the pathologic TRG (MSKCC score) was calculated by 
means of ANOVA test, after assaying normality of residuals. 
An association was found without reaching statistical 
significance (P=0.58) Figure 2.
Correlation between metabolic response by PET/CT 
scan and pathologic TRG was also studied. A positive but 
poor correlation was observed (rho =0.32; Spearman test) 
and without statistical significance (P=0.25). 
Discussion
Currently, one of the most intriguing challenges in the 
management of patients with LACC is the way to select 
those who may benefit most from a neoadjuvant strategy. 
In this sense, the accuracy of imaging seems critical. 
Reported accuracy rates for CT in the preoperative staging 
of colon cancer range between 41% and 82% (11-14). In 
recent years, the use of oral and rectal contrast agents has 
improved the determination of the depth of invasion through 
the colonic wall, and MDCT has provided the additional 
capability of using thin collimation that offer an improved 
quality of MPRs and better spatial resolution. Despite thin 
sections, however, an intrinsic limitation of CT is the lack 
of visualization of the individual wall layers. The sensitivity 
of CT in detection of primary colon cancer is variable and 
depends on the size of the tumor. In this study we have found 
an accuracy of 62% (27/44) for T stage, within the range of 
that reported in the literature (15-17).
Another limitation of the CT staging relies on its inability 
to definitively distinguish metastatic lymph nodes. Small 
nodes may harbor tumor, and enlarged nodes may not. As 
expected, the sensitivity of CT for detection of malignant 
nodes decreased when applying the 1-cm threshold 
instead of a 0.8-cm threshold. Accuracy rates for N stage 
in recent papers range between 22% and 77% (17-19). 
In the present work, an accuracy of 87% (38/44) was 
achieved for N stage.
18F-FDG PET is a molecular imaging technique that 
visualizes and quantifies metabolic processes in cancer 
cells. PET has experienced an explosive growth as a 
diagnostic modality, especially in the realm of oncology 
for tumor staging, restaging, surveillance of recurrence 
and monitoring treatment response (20-22). PET/CT 
scans provide fused functional and morphological imaging, 
overcoming the lack of anatomical information of FDG-
PET. There is an increasing interest in the role of FDG-
PET for the prediction of tumor response to therapy, as 
it has been shown in lymphomas and esophageal cancer 
(23-26). Predictors of response in LACC are eagerly 
awaited due to the presumed favorable prognostic value 
of a complete response to neoadjuvant therapy in terms of 
improved survival times and the possibility of performing 
less aggressive surgical approaches (27-29).
Neoadjuvant strategies require highly accurate diagnostic 
tests for a proper selection of candidate patients (18-30). 
The reported accuracy for TN classification of 77%, with 
a low rate of overstaging, suggests that patient selection 
for neoadjuvant chemotherapy on the basis of currently 
available image techniques is promising. Nevertheless, 
prospective trials to rule out the best imaging workout to be 
performed with the highest accuracy seem warranted.
This study found a trend toward statistical significance in the 
relationship between the change in tumor volume measured 
by CT and the degree of pathological regression. This absence 
of significance might be due to the lack of statistical power. 
Similar results were found when assessing the correlation 
between metabolic and pathological response. These findings 
might allow considering the PET/TC to be a predictor tool of 
pathological response in the LACC in the future.
This study has some limitations that deserve consideration. 
This is a single institutional experience and recorded in a 
retrospective way. On the other hand we had few patients, 
Figure 2 Relation between volume reduction and pathologic 
response grade.
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which obligate the results to be handled with caution.
Conclusions
Neoadjuvant chemotherapy based on oxaliplatin and 
capecitabine for LACC induces a significative tumor 
response that can be measured at radiologic, metabolic and 
pathologic level. The accuracy and the low overstaging 
of CT scan may allow LACC patients to benefit from a 
neoadjuvant therapy with a low risk of overtreatment.
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